This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

GUARD BTA Stock Overview

A pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. More details

GUARD BTA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 9% per year for the next 3 years

Makes less than USD$1m in revenue (SEK0)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Guard Therapeutics International AB (publ) Competitors

Medivir

OM:MVIR

SEK 166.0m

Alzinova

OM:ALZ

SEK 226.5m

Lipum

OM:LIPUM

SEK 339.4m

SynAct Pharma

OM:SYNACT

SEK 751.3m

Price History & Performance

Summary of share price highs, lows and changes for Guard Therapeutics International
Historical stock prices
Current Share Price	SEK 26.40
52 Week High	SEK 28.00
52 Week Low	SEK 22.20
Beta	-0.077
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	17.86%

Recent updates

Shareholder Returns

	GUARD BTA	SE Biotechs	SE Market
7D	8.2%	0.2%	-1.4%
1Y	n/a	1.1%	2.0%

Return vs Industry: Insufficient data to determine how GUARD BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how GUARD BTA performed against the Swedish Market.

Price Volatility

Is GUARD BTA's price volatile compared to industry and market?
GUARD BTA volatility
GUARD BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.8%
Market Average Movement	6.1%
10% most volatile stocks in SE Market	12.9%
10% least volatile stocks in SE Market	3.5%

Stable Share Price: GUARD BTA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: Insufficient data to determine GUARD BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	11	Tobias Agervald	guardtherapeutics.com

Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019.

Guard Therapeutics International AB (publ) Fundamentals Summary

How do Guard Therapeutics International's earnings and revenue compare to its market cap?
GUARD BTA fundamental statistics
Market cap	SEK 323.10m
Earnings (TTM)	-SEK 78.82m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.1x

P/E Ratio

Is GUARD BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GUARD BTA income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 78.82m
Earnings	-SEK 78.82m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-6.54
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did GUARD BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/10/09 12:11
End of Day Share Price	2024/10/09 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Guard Therapeutics International AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ludvig Svensson	Carnegie Commissioned Research
Lars Hevreng	Danske Bank
Hans Mähler	Nordea Markets

Guard Therapeutics International OM:GUARD BTA Stock Report